Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
7 studies found for:    parp prostate cancer | Open Studies
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting Studying the Effects of Olaparib (± Degarelix) Given to Men With Intermediate/High Risk Prostate Cancer Before Radical Prostatectomy
Condition: Prostate Cancer
Interventions: Drug: Olaparib;   Drug: Degarelix
2 Recruiting A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
Condition: Metastatic Castration Resistant Prostate Cancer
Intervention: Drug: Rucaparib
3 Recruiting A Study of Rucaparib Verses Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
Condition: Metastatic Castration Resistant Prostate Cancer
Interventions: Drug: Rucaparib;   Drug: Abiraterone acetate or Enzalutamide or Docetaxel
4 Recruiting An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies
Condition: Prostatic Neoplasms
Intervention: Drug: Niraparib
5 Recruiting Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
Conditions: Prostate Cancer Metastatic Castration-Resistant;   Abnormal DNA Repair;   Metastatic Prostate Carcinoma;   Stage IV Prostate Cancer
Interventions: Drug: Olaparib;   Drug: Abiraterone Acetate;   Drug: Prednisone
6 Recruiting Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers
Conditions: Lung Cancer;   Breast Cancer;   Ovarian Cancer;   Colorectal Cancer;   Prostate Cancer;   Triple Negative Breast Cancer
Interventions: Drug: Olaparib;   Drug: Cediranib;   Drug: MEDI4736
7 Recruiting A Study of SC10914 in Patients With Advanced Solid Tumors
Condition: Advanced Solid Tumors
Intervention: Drug: SC10914

Study has passed its completion date and status has not been verified in more than two years.